Konstantin E. Seifert

MD Urology, Uro-oncology @UK_Muenster

[Konstantin E. Seifert @seifert_ke]

@niklas_kluemper @CCR_AACR @AACR Congratulations! Nice work!

[Niklas Klümper @niklas_kluemper]

Happy to share our new paper in Clinical Cancer Research on NECTIN4 as a biomarker for enfortumab vedotin in urothelial cancer! @CCR_AACR @AACR

An important clue was already present in EV-301: patients with higher NECTIN4 IHC (H-score >150) had an ORR of 45.8% vs 20.0% with lower expression.

We now take this one step further and show that localization matters:

🎯 Membranous NECTIN4 correlates with EV response — cytoplasmic NECTIN4 does not.

This makes biological sense for an ADC: EV needs to bind its target on the tumor-cell surface to internalize and deliver its payload.

We further integrate NECTIN4 amplification + membranous protein expression, moving toward a more precise biomarker framework for EV.

For ADC biomarkers, it is not simply whether a target is expressed — but how much, where, and in which tumor lesion.

Hopefully another step toward precision ADC therapy in urothelial cancer.

Thanks to a great team and my collaborators! @Markuseckstein3 @KuppeChristoph @braegelmannlab @JoshMeeks @HolzelMichael

https://t.co/e1IhJTy2ij

@OncoAlert @weoncologists @DrChoueiri

@Uroweb @AmerUrological @ASCO @PathSoc @OncoAlert @Histo_Journal @andreanecchi @emanuele_crupi @danieleraggi83 @raffcolo @Dr_Aggen @DrRosenbergMSK @h_alahmadie @PGrivasMDPhD @shilpaonc @drenriquegrande @amerseburger @brookmans76 @DrYukselUrun @onkowissen @imedverse @UroDocAsh @urotoday @EUplatinum @JCO_ASCO @CCR_AACR @niklas_kluemper @DrRosenbergMSK @Dr_Aggen @Uromigos @tompowles1 @shilpaonc @PGrivasMDPhD

[JNM @JournalofNucMed]

Dynamic changes in ⁶⁸Ga-HER2 PET/CT uptake during neoadjuvant therapy provide an effective early indicator of therapeutic sensitivity in HER2-positive breast cancer. https://t.co/ayx7jdoVqq

#NuclearMedicine

[European Urology @EUplatinum]

📢 New publication in European Urology

We are pleased to highlight a new study published in European Urology, titled “Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [68Ga]Ga-OncoACP3-DOTA”.

👏 Congratulations to Philipp Backhaus, Samuele Cazzamalli, Seifert E., and Schäfers M. on this excellent contribution, together with all co-authors.

🔗 Read the full article here:
👉 https://t.co/MWy0LQdYFD

#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology

[Konstantin E. Seifert @seifert_ke]

Nice Phase 1 results of OncoACP3 a prostatic Acid phosphatase (ACP3) direct radioligand!

https://t.co/6E1mNQ9ITM

[UroToday.com @urotoday]

The LuRa Study: Safety and survival outcomes of radium-223 in patients with #mCRPC with prior 177Lu-PSMA radioligand therapy. Presentation by @Dr_K_Rahbar @UK_Muenster. #SNMMI26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/zIbGbtiRZY @SNM_MI

[OncoAlert @OncoAlert]

Coverage of #APCCC26 🇨🇭 by @OncoAlert 🚨 Day Three
PSMA plus: New tracers and equipment technologies to improve accuracy that are close to clinical implementation Presenter Dr. Ken Herrmann 🇩🇪

Conclusions
• No new beyond PSMA RLT ready for near time implementation
• Long list of exciting new targets
• My personal favorites: ACP3, STEAP1/2 and B7-H3

#ProstateCancer #ProstateCancerWeek

@APCCC_Lugano
@Silke_Gillessen
@AOmlin
@weoncologists
@declangmurphy
@RenuEapen
@DrYukselUrun
@nataliagandur
@fabioturco92
@UrsulaVogl
@SScagliarini
@Tylersbrt
@neerajaiims
@amerseburger
@Cdanicas
@AarmstrongDuke
@BertrandTOMBAL
@ChrisSweens1
@EAntonarakis
@KOSJ12
@VedangMurthy
@DrRanaMcKay
@LoebStacy
@stefanofanti4
@mirrorsmed
@profkhermann
@dr_coops
@piet_ost
@_ShankarSiva
@DrSpratticus
@scocmem
@AmandaNizamMD
@tompowles1
@brian_rini
@dmukherji
@Uromigos
@EUplatinum
@EANM_NucMed
@ESTRO_RT
@Uroweb

[European Urology @EUplatinum]

SPOTLIGHT: Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [68Ga]Ga-OncoACP3-DOTA by Philipp Backhauset al

#Spotlights #EURUROL #PCa #ProstateCancer #78

[Konstantin E. Seifert @seifert_ke]

The prostatic acid phosphatase: The new kid on the block for theranostics in prostate cancer.

Our Review now published in Seminars in Nuclear Medicine gives an overview of what we know so far!

https://t.co/zUWemeypMV

@urotoday @PSMAconference

[Toni Choueiri, MD @DrChoueiri]

9️⃣ years later, the story of dual immune checkpoint blockade in metastatic RCC is still being written.

The final "very" long-term follow-up of CheckMate-214 confirms what many hoped in 2018: durable survival, deep responses, and a subset of patients who may experience long-term disease control with nivolumab + ipilimumab.

A short 🧵 on what 9+ years of follow-up teach us about immunotherapy in kidney cancer since Bernard Escudier @myESMO 2018 plenary presentation

https://t.co/l77lPkeLrl

[Konstantin E. Seifert @seifert_ke]

@LouiseKostos @APCCC_Lugano @Silke_Gillessen @Uromigos @DrMHofman @urotoday @niklas_kluemper @PSMAconference @ViktorGruenwald

[Konstantin E. Seifert @seifert_ke]

Excited to share our new @EUplatinum paper on first-in-human PET imaging targeting ACP3 with a novel ⁶⁸Ga tracer-offering a potential alternative to PSMA imaging in prostate cancer.

Proud to be co-senior author.

https://t.co/2Ac7f8Ug5f

[Andrea Necchi, MD, FASCO @AndreaNecchi]

Out in @ESMO_Open @myESMO an important study led by @BrigidaMaiorano:
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study https://t.co/IQljedaMyb @UroDocAsh @SpiessPhilippe @montypal @neerajaiims @shilpaonc @CMercinelli @vale_tateo @Anto_cigliola @gio_pasto_real @urotoday @OncoAlert

[Konstantin E. Seifert @seifert_ke]

Great biomarker work! Always important to gain better understanding what Pat Profit Most from dif therapies in mCRPC!

By @AzadOncology @LouiseKostos @PeterMacCC

https://t.co/PgcPuC3FS7

[Konstantin E. Seifert @seifert_ke]

@Uromigos Biggest impact probably PARPi for selected patients, but I guess greatest n of Patients docetaxel

[Konstantin E. Seifert @seifert_ke]

@PCFnews @DrMHofman Is there any chance to rewatch it somewhere?

[Konstantin E. Seifert @seifert_ke]

Great overview! There is definitely more to come, novel Targets + new Isotopes may help to overcome resistance.

[Uromigos @Uromigos]

Radioisotopes in prostate cancer are expanding quickly. @anis_a_hamid describes novel targets such as potential (STEAP2, hK2) as well as novel combination (IO, chemo, PARPi). Optimal dosing is uncertain & also addressed as well as new isotopes such as actinium or lead @OncoAlert

[UroToday.com @urotoday]

Imaging and treatment of the prostatic acid phosphatase with 68Ga-OncoACP3-DOTA and 177Lu-OncoACP3-DOTA in #ProstateCancer patients. Presentation by @seifert_ke. #ESMO25 written coverage by @zklaassen_md > https://t.co/TdWHBxnzgN @myESMO

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science

[Konstantin E. Seifert @seifert_ke]

@DrMHofman @myESMO @LouiseKostos @TheLancetOncol Not allowing babies is a shame! @myESMO Should reconsider Its rules! As Long you can only carry your child it should be allowed!